No Carolina / NY / Florida
Ph: 561.316.3330

Perimeter Medical Imaging AI Announces Further Commercial Expansion in North Texas with Follow-On Placement of Perimeter S-Series OCT within National Healthcare Provider System

Summation

  • Or the “Company”) – a commercial-stage medical technology company – today announced a follow-on commercial placement of its flagship Perimeter S-Series OCT system at a new hospital site within one of the largest healthcare networks in North Texas, which is part of a major national healthcare system.
  • Adrian Mendes, Perimeter’s Chief Executive Officer, stated, “We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers.
  • Perimeter’s flagship product, the S-Series OCT (Optical Coherence Tomography), is a pioneering medical imaging system that provides cross-sectional, real-time margin visualization of excised tissue specimens in the operating room at 10 times higher image resolution than X-ray and ultrasound, and 100 times greater image resolution than MRI.

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company – today announced a follow-on commercial placement of its flagship Perimeter S-Series OCT system at a new hospital site within one of the largest healthcare networks in North Texas, which is part of a major national healthcare system.

Perimeter’s flagship product, the S-Series OCT (Optical Coherence Tomography), is a pioneering medical imaging system that provides cross-sectional, real-time margin visualization of excised tissue specimens in the operating room at 10 times higher image resolution than X-ray and ultrasound, and 100 times greater image resolution than MRI.

Adrian Mendes, Perimeter’s Chief Executive Officer, stated, “We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers. Our aim is to make Perimeter’s innovative technology the standard of care in cancer surgery.”

More News

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy